Grover disease shows type 2 immune activation and improves with dupilumab
Michael J. Murphy(American Veterinary Medical Association), William Damsky(Yale University), Jeffrey M. Cohen(Yale University), Muhammad Hyder Junejo(Yale University), Caroline A Nelson(Yale University), Okeroghene Rufin(Yale University)
Cited by 2
Related Papers
Computationally guided personalized targeted ablation of persistent atrial fibrillation
|Nature Biomedical Engineering|2019|318
Compendium of Experimental Cetane Number Data
|Unknown|2004|263
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
|Cell|2024|175
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
|Journal of the American Academy of Dermatology|2020|157
Hereditary myokymia and periodic ataxia
|Journal of the Neurological Sciences|1975|132